OBJECTIVES: The objective of the study was to investigate change in bone mineral density (BMD) over time in HIV-infected women in comparison with healthy control subjects similar in age, race, and body mass index (BMI). DESIGN: This was a prospective cohort study. METHODS: BMD was measured by dual-energy x-ray absorptiometry in 100 HIV-infected females and 100 healthy controls similar in age (41 +/- 1 vs. 41 +/- 1 yr, P = 0.57), BMI (26.1 +/- 0.5 vs. 27.2 +/- 0.4 kg/m(2), P = 0.12), and race (60 vs. 65% non-Caucasian, P = 0.47, HIV-infected vs. controls). Changes in BMD were determined every 6 months over 24 months. RESULTS: At baseline, HIV-infected subjects had lower BMD at the lumbar spine (1.01 +/- 0.01 vs. 1.07 +/- 0.01 g/cm(2), P = 0.001), hip (0.94 +/- 0.01 vs. 0.98 +/- 0.01 g/cm(2), P = 0.02), and femoral neck (0.83 +/- 0.01 vs. 0.87 +/- 0.01 g/cm(2), P = 0.02). Historical low weight, duration of nucleoside reverse transcriptase inhibitor use, and FSH were significantly associated with lumbar BMD, whereas duration of HIV, BMI, historical low weight, smoking pack-years, N-telopeptide of type 1 collagen, viral load, 25 hydroxyvitamin D, and osteocalcin were associated with hip BMD at baseline. In mixed model longitudinal analyses, BMD remained lower in HIV-infected subjects than in controls over 24 months of follow-up (P = 0.001 for the spine, P = 0.04 for the hip, and P = 0.02 for the femoral neck). These differences remained significant controlling for age, race, BMI, and menstrual function. In contrast, rates of change for the spine (P = 0.79), hip (P = 0.44), and femoral neck (P = 0.34) were not different between the HIV and control groups over 2 yr. In the HIV group, longitudinal changes in BMD were not associated with current protease inhibitor, nucleoside reverse transcriptase inhibitor, or non-nucleoside reverse transcriptase inhibitor use but were associated with CD4 count, weight, FSH, N-telopeptide of type 1 collagen, and baseline BMD. CONCLUSIONS: BMD is reduced at the spine, hip, and femoral neck among women with HIV in relationship to low weight, duration of HIV, smoking, and increased bone turnover. Over 2 yr of follow-up, BMD remained stable but lower in HIV-infected women, compared with control subjects.
OBJECTIVES: The objective of the study was to investigate change in bone mineral density (BMD) over time in HIV-infectedwomen in comparison with healthy control subjects similar in age, race, and body mass index (BMI). DESIGN: This was a prospective cohort study. METHODS: BMD was measured by dual-energy x-ray absorptiometry in 100 HIV-infected females and 100 healthy controls similar in age (41 +/- 1 vs. 41 +/- 1 yr, P = 0.57), BMI (26.1 +/- 0.5 vs. 27.2 +/- 0.4 kg/m(2), P = 0.12), and race (60 vs. 65% non-Caucasian, P = 0.47, HIV-infected vs. controls). Changes in BMD were determined every 6 months over 24 months. RESULTS: At baseline, HIV-infected subjects had lower BMD at the lumbar spine (1.01 +/- 0.01 vs. 1.07 +/- 0.01 g/cm(2), P = 0.001), hip (0.94 +/- 0.01 vs. 0.98 +/- 0.01 g/cm(2), P = 0.02), and femoral neck (0.83 +/- 0.01 vs. 0.87 +/- 0.01 g/cm(2), P = 0.02). Historical low weight, duration of nucleoside reverse transcriptase inhibitor use, and FSH were significantly associated with lumbar BMD, whereas duration of HIV, BMI, historical low weight, smoking pack-years, N-telopeptide of type 1 collagen, viral load, 25 hydroxyvitamin D, and osteocalcin were associated with hip BMD at baseline. In mixed model longitudinal analyses, BMD remained lower in HIV-infected subjects than in controls over 24 months of follow-up (P = 0.001 for the spine, P = 0.04 for the hip, and P = 0.02 for the femoral neck). These differences remained significant controlling for age, race, BMI, and menstrual function. In contrast, rates of change for the spine (P = 0.79), hip (P = 0.44), and femoral neck (P = 0.34) were not different between the HIV and control groups over 2 yr. In the HIV group, longitudinal changes in BMD were not associated with current protease inhibitor, nucleoside reverse transcriptase inhibitor, or non-nucleoside reverse transcriptase inhibitor use but were associated with CD4 count, weight, FSH, N-telopeptide of type 1 collagen, and baseline BMD. CONCLUSIONS: BMD is reduced at the spine, hip, and femoral neck among women with HIV in relationship to low weight, duration of HIV, smoking, and increased bone turnover. Over 2 yr of follow-up, BMD remained stable but lower in HIV-infectedwomen, compared with control subjects.
Authors: J Teichmann; E Stephan; T Discher; U Lange; K Federlin; H Stracke; G Friese; J Lohmeyer; R G Bretzel Journal: Metabolism Date: 2000-09 Impact factor: 8.694
Authors: Giordano Madeddu; A Spanu; P Solinas; G M Calia; C Lovigu; F Chessa; M Mannazzu; A Falchi; M S Mura; Giuseppe Madeddu Journal: Q J Nucl Med Mol Imaging Date: 2004-03 Impact factor: 2.346
Authors: Todd T Brown; Mary D Ruppe; Rory Kassner; Princy Kumar; Theresa Kehoe; Adrian S Dobs; Joseph Timpone Journal: J Clin Endocrinol Metab Date: 2004-03 Impact factor: 5.958
Authors: Sara E Dolan; Jeannie S Huang; Kathleen M Killilea; Meghan P Sullivan; Negar Aliabadi; Steven Grinspoon Journal: AIDS Date: 2004-02-20 Impact factor: 4.177
Authors: J Fernández-Rivera; R García; F Lozano; J Macías; J A García-García; J A Mira; J E Corzo; J Gómez-Mateos; A Rueda; J Sánchez-Burson; J A Pineda Journal: HIV Clin Trials Date: 2003 Sep-Oct
Authors: Kristine M Erlandson; Douglas Kitch; Camlin Tierney; Paul E Sax; Eric S Daar; Pablo Tebas; Kathleen Melbourne; Belinda Ha; Nasreen C Jahed; Grace A McComsey Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: Ariana Darcy; Micah Meltzer; Joseph Miller; Steven Lee; Scott Chappell; Kris Ver Donck; Monty Montano Journal: Bone Date: 2012-03-13 Impact factor: 4.398
Authors: D D Byrne; C W Newcomb; D M Carbonari; M S Nezamzadeh; K B F Leidl; M Herlim; Y X Yang; S Hennessy; J R Kostman; M B Leonard; A R Localio; V Lo Re Journal: J Viral Hepat Date: 2015-03-06 Impact factor: 3.728
Authors: Michael T Yin; Don J McMahon; David C Ferris; Chiyuan A Zhang; Aimee Shu; Ronald Staron; Ivelisse Colon; Jeffrey Laurence; Jay F Dobkin; Scott M Hammer; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2009-12-04 Impact factor: 5.958
Authors: Anjali Sharma; Qiuhu Shi; Donald R Hoover; Kathryn Anastos; Phyllis C Tien; Mary A Young; Mardge H Cohen; Elizabeth T Golub; Deborah Gustafson; Michael T Yin Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731